Organization
Japan Association for Development of Community Medicine
13 abstracts
Abstract
Interactive assistance via eHealth for small- and medium-sized enterprises’ employer and health care manager teams on tobacco control (eSMART-TC): A cluster randomized hybrid type II trial (N-EQUITY2101/J-SUPPORT2102).Org: National Cancer Center Institute for Cancer Control, Graduate School of Health Innovation, Kanagawa University of Human Services, Research Center for Health Policy and Economics, Hitotsubashi Institute for Advanced Study,
Abstract
Associations between prognosis and primary endpoint selection in phase III oncology trials in the United States.Org: The University of Tokyo, Tokyo, Japan, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan Association for Development of Community Medicine,
Abstract
A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.Org: National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa-Shi, Japan Association for Development of Community Medicine, Graduate School of Medicine Chiba University, Chiba, Japan,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Cancer Institute of the State of São Paulo, São Paulo, Brazil, São Paulo, Brazil, Brazil,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
Induction and concomitant chemoradiotherapy (CCRT) using modified TPF (docetaxel, cisplatin and 5-FU) for the patients with stage IVB advanced head and neck cancer.Org: Iwate Medical University, Morioka, Japan, Japan Association for Development of Community Medicine, Yahaba,
Abstract
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).Org: Department of Thoraci surgery, National Cancer Center Hospital East, Kashiwa, Japan, Division of Thoracic and Thyroid Surgery, Tokyo Medical University, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,
Abstract
Effect of lymph node dissection and adjuvant therapy in patients with sentinel node+ melanoma: An observational multicenter study.Org: National Cancer Center Hospital East, Kashiwa, Japan, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan Association for Development of Community Medicine, Nagoya University Graduate School of Medicine, Aichi Cancer Center Hospital,
Abstract
ANTIINFLAMMATORY AND JOINT PROTECTIVE EFFECT OF SMP-114 IN MURINE COLLAGEN-INDUCED ARTHRITISOrg: Research Center for Health Policy and Economics, Sumitomo Pharmaceuticals, Osaka International Cancer Institute, Osaka, Japan, Japan Association for Development of Community Medicine,
Abstract
AUTOANTIBODIES TO CYCLIC CITRULLINATED PEPTIDE 2 (CCP2) ARE SUPERIOR TO OTHER POTENTIAL DIAGNOSTIC BIOMARKERS FOR PREDICTING DEVELOPMENT OF RHEUMATOID ARTHRITIS (RA) IN EARLY UNDIFFERENTIATED ARTHRITISOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Allergy Therapeutics, Clinical Research Centre, Cardiology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, NHO Osaka-Minami Medical Center,
Abstract
ANEMIA IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK INHIBITORSOrg: Sanuki municipal hospital, Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Kagawa University Hospital, Japan Association for Development of Community Medicine,
Abstract
ASSOCIATION OF RHEUMATOID FACTOR AND ANTI-CITRULLINATED PROTEIN ANTIBODY STATUS WITH ORTHOPEDIC SURGERIES FOR RHEUMATOID ARTHRITIS PATIENTS Org: The Centre For Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan, Matsuyama Red Cross Hospital, Ehime University Hospital, Toon, Ehime, Japan, Japan Association for Development of Community Medicine,